Literature DB >> 28919989

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.

Aurélie Hanoteau1, Coralie Henin1, David Svec2, Charlotte Bisilliat Donnet1, Sébastien Denanglaire1, Didier Colau3, Pedro Romero4, Oberdan Leo1, Benoit Van den Eynde3, Muriel Moser1.   

Abstract

An important question is how chemotherapy may (re-)activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8+ T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re-engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.

Entities:  

Keywords:  CD8+ T cells; cyclophosphamide; effector function; exhaustion; tumor-specific immunity

Year:  2017        PMID： 28919989      PMCID： PMC5593741          DOI： 10.1080/2162402X.2017.1318234

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  35 in total

1.  Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments.

Authors:  Qing Ge; Hui Hu; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

2.  Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo.

Authors:  Melanie Wiesel; Josh Crouse; Gregor Bedenikovic; Andrew Sutherland; Nicole Joller; Annette Oxenius
Journal:  Eur J Immunol       Date:  2011-12-20       Impact factor: 5.532

3.  KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells.

Authors:  Sian M Henson; Ornella Franzese; Richard Macaulay; Valentina Libri; Rita I Azevedo; Sorena Kiani-Alikhan; Fiona J Plunkett; Joanne E Masters; Sarah Jackson; Stephen J Griffiths; Hans-Peter Pircher; Maria V D Soares; Arne N Akbar
Journal:  Blood       Date:  2009-04-30       Impact factor: 22.113

4.  Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.

Authors:  J Bilsborough; A Van Pel; C Uyttenhove; T Boon; B J Van den Eynde
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

5.  Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Authors:  Lionel Apetoh; Mark J Smyth; Charles G Drake; Jean-Pierre Abastado; Ron N Apte; Maha Ayyoub; Jean-Yves Blay; Marc Bonneville; Lisa H Butterfield; Anne Caignard; Chiara Castelli; Federica Cavallo; Esteban Celis; Lieping Chen; Mario P Colombo; Begoña Comin-Anduix; Georges Coukos; Madhav V Dhodapkar; Glenn Dranoff; Ian H Frazer; Wolf-Hervé Fridman; Dmitry I Gabrilovich; Eli Gilboa; Sacha Gnjatic; Dirk Jäger; Pawel Kalinski; Howard L Kaufman; Rolf Kiessling; John Kirkwood; Alexander Knuth; Roland Liblau; Michael T Lotze; Enrico Lugli; Francesco Marincola; Ignacio Melero; Cornelis J Melief; Thorsten R Mempel; Elizabeth A Mittendorf; Kunle Odun; Willem W Overwijk; Anna Karolina Palucka; Giorgio Parmiani; Antoni Ribas; Pedro Romero; Robert D Schreiber; Gerold Schuler; Pramod K Srivastava; Eric Tartour; Danila Valmori; Sjoerd H van der Burg; Pierre van der Bruggen; Benoît J van den Eynde; Ena Wang; Weiping Zou; Theresa L Whiteside; Daniel E Speiser; Drew M Pardoll; Nicholas P Restifo; Ana C Anderson
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

Review 6.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

9.  Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs.

Authors:  Fernando Cruz-Guilloty; Matthew E Pipkin; Ivana M Djuretic; Ditsa Levanon; Joseph Lotem; Mathias G Lichtenheld; Yoram Groner; Anjana Rao
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

10.  Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates.

Authors:  Surojit Sarkar; Vandana Kalia; W Nicholas Haining; Bogumila T Konieczny; Shruti Subramaniam; Rafi Ahmed
Journal:  J Exp Med       Date:  2008-03-03       Impact factor: 14.307
View more
  7 in total

Review 1.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 2.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

3.  Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients.

Authors:  Belinda Palermo; Ornella Franzese; Cosmo Di Donna; Mariangela Panetta; Concetta Quintarelli; Isabella Sperduti; Novella Gualtieri; Maria Laura Foddai; Enrico Proietti; Virginia Ferraresi; Gennaro Ciliberto; Paola Nisticò
Journal:  Oncoimmunology       Date:  2018-09-11       Impact factor: 8.110

4.  Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.

Authors:  Jared M Newton; Aurelie Hanoteau; Hsuan-Chen Liu; Angelina Gaspero; Falguni Parikh; Robyn D Gartrell-Corrado; Thomas D Hart; Damya Laoui; Jo A Van Ginderachter; Neeraja Dharmaraj; William C Spanos; Yvonne Saenger; Simon Young; Andrew G Sikora
Journal:  J Immunother Cancer       Date:  2019-08-13       Impact factor: 13.751

5.  Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies.

Authors:  R Eftimie; G Eftimie
Journal:  Acta Biotheor       Date:  2019-08-13       Impact factor: 1.774

6.  Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Authors:  Aurelie Hanoteau; Jared M Newton; Rosemarie Krupar; Chen Huang; Hsuan-Chen Liu; Angelina Gaspero; Robyn D Gartrell; Yvonne M Saenger; Thomas D Hart; Saskia J Santegoets; Damya Laoui; Chad Spanos; Falguni Parikh; Padmini Jayaraman; Bing Zhang; Sjoerd H Van der Burg; Jo A Van Ginderachter; Cornelis J M Melief; Andrew G Sikora
Journal:  J Immunother Cancer       Date:  2019-01-15       Impact factor: 13.751

7.  Heterogeneity and clonality of kidney-infiltrating T cells in murine lupus nephritis.

Authors:  Shuchi Smita; Maria Chikina; Mark J Shlomchik; Jeremy S Tilstra
Journal:  JCI Insight       Date:  2022-04-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.